Brief: Ocumension Therapeutics Says Ind Application Received For A Phase Iii Clinical Trial Of Ot-101 In China
11/05/2021 09:24
May 11 (Reuters) - Ocumension Therapeutics 1477.HK :
* OCUMENSION THERAPEUTICS ANNOUNCES IND APPLICATION RECEIVED
FOR A
PHASE III CLINICAL TRIAL OF OT-101 IN CHINA
Source text for Eikon: ID:nHKS9Tcf3
Further company coverage: 1477.HK
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application